Perspective Therapeutics, Inc.
CATX
$2.99
-$0.13-4.17%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -72.07% | -77.78% | -81.62% | -43.36% | -44.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.07% | -77.78% | -81.62% | -43.36% | -44.87% |
| Cost of Revenue | 29.63% | 49.12% | 155.56% | 69.10% | 79.19% |
| Gross Profit | -31.43% | -52.22% | -159.95% | -72.66% | -86.65% |
| SG&A Expenses | 1.12% | -10.93% | -15.70% | 10.84% | 39.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.59% | 27.88% | 88.72% | 47.71% | 64.51% |
| Operating Income | -21.71% | -29.54% | -90.63% | -49.52% | -68.54% |
| Income Before Tax | -22.66% | -44.08% | 9.42% | -71.73% | -96.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.66% | -44.08% | 6.67% | -71.73% | -96.17% |
| Earnings from Discontinued Operations | -61.67% | -- | -- | -- | 204.90% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.67% | -44.08% | 6.67% | -71.73% | -83.57% |
| EBIT | -21.71% | -29.54% | -90.63% | -49.52% | -68.54% |
| EBITDA | -20.64% | -28.70% | -92.28% | -50.77% | -70.23% |
| EPS Basic | 23.29% | -0.64% | 16.34% | -63.24% | -64.81% |
| Normalized Basic EPS | 24.51% | -0.64% | -96.76% | -63.30% | -76.05% |
| EPS Diluted | 23.29% | -0.64% | 16.34% | -63.24% | -64.81% |
| Normalized Diluted EPS | 24.51% | -0.64% | -96.76% | -63.30% | -76.05% |
| Average Basic Shares Outstanding | 62.53% | 43.18% | 15.39% | 5.19% | 11.38% |
| Average Diluted Shares Outstanding | 62.53% | 43.18% | 15.39% | 5.19% | 11.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |